FT  03 NOV 93 / International Company News: Merck drug withdrawn
MERCK yesterday withdrew Roxiam, a schizophrenia treatment which was
awaiting approval from the US Food and Drug Administration. The move follows
the death of a patient in Europe, write Richard Waters and Paul Abrahams in
New York.
The drug, which has been marketed in Europe by Astra, the Swedish company,
for the past two and a half years, was said by analysts to have the
potential for peak annual sales of Dollars 100m-Dollars 250m in the US.
The withdrawal followed the development of a blood disorder in eight
patients taking the drug in Europe.
